| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces the completion of patient enrollment ...
HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and maintains $37 price target.
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.
Outlook/Summary For 2024, the Company anticipates: Total revenues between US$280 million and US$295 million (14% to 20% gro...
Pharming (NASDAQ:PHAR) reported quarterly earnings of $0.00 per share. This is a 120 percent increase over losses of $(0.02) pe...
Pharming Group (NASDAQ: PHAR) updated its full-year 2023 guidance, including RUCONEST and Joenja revenues, and a progress updat...
Preliminary, unaudited cash and cash equivalents, together with restricted cash and marketable securities, are expected to to...
Leiden, The Netherlands, December 13, 2023: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) ann...
Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM)/(NASDAQ:PHAR) announces that the ...
